Overview

• Anne Wojcicki, co-founder of 23andMe, is considering taking the company private after significant market valuation losses.
• The company's valuation plummeted from a high of $6 billion at its public debut in 2021 to being virtually worthless.
• Wojcicki intends to retain control and is not open to alternative acquisition offers, holding about 49% of the voting power.
• 23andMe has struggled with declining revenues and failed attempts to create a recurring revenue stream through subscriptions.
• The move to privatize aims to secure more flexible funding for potential drug development leveraging its DNA database.